Compounded GLP-1 advertising claims the FDA flags

FDA treats false or misleading promotion of a compounded drug as misbranding. Its warning letters to telehealth companies flag five types of compounded GLP-1 advertising claims: calling the drug “generic” or the same as an approved drug, claiming FDA approval, “clinically proven” results, “FDA-licensed” sourcing, and labels that make the brand look like the compounder.

Policy checked on October 26, 2026.

What FDA tells telehealth companies about compounded drug claims

FDA’s guidance page for telehealth companies (current as of June 15, 2026) lists the claims it considers false or misleading. It starts from one fact: “a compounded drug is not approved by FDA.” The list covers calling a compounded drug a generic, presenting it as identical to an approved brand, claiming FDA approval, borrowing the approved drug’s trial results, calling the pharmacy FDA-licensed, and branding that suggests the telehealth company makes the drug.

All 4 letters in the table below cite FD&C Act sections 502(a) (misleading labeling) and 502(bb) (misleading advertising or promotion of a compounded drug).

Compounded GLP-1 claims in FDA letters, phrase by phrase

FDA’s letters quoted these compounded GLP-1 phrases from telehealth company websites. Each row matches a phrase to a claim type on FDA’s page.

Every phrase came from a company website, not a paid ad. Ad copy usually borrows from the landing page, so check both.

How often online ads for compounded GLP-1s made these claims

In 2024, more than a third of websites selling compounded GLP-1s stated or implied FDA approval. A JAMA Health Forum study (January 17, 2025) reviewed 79 such websites, found in the sponsored results of Google Shopping searches run from July to September 2024.

Source: Chetty et al., JAMA Health Forum.

Enforcement timeline for compounded GLP-1 marketing

FDA has sent compounded GLP-1 marketing letters in waves since September 2025. All dates come from FDA pages except the NAD row.

Where Meta and Google ad policies fit

Meta and Google decide whether a telehealth brand may run prescription drug ads at all; FDA’s rules decide what the ads may claim. Neither platform’s main policy page mentions compounded drugs (we checked Meta’s Drugs and Pharmaceuticals policy and Google’s Healthcare and medicines policy on October 26, 2026). Eligibility rules are covered in Meta’s GLP-1 prescription drug ad rules and Google Ads telemedicine certification.

Review list before a compounded GLP-1 campaign goes live

Before launch, check every place FDA’s letters looked, plus the brand-controlled pages the letters didn’t cover.

1. Ad copy, keywords, landing pages and FAQs: none of the phrases in the table, including “FDA-licensed” sourcing lines.
2. Product photos and ad images: whose name is on the pictured label.
3. Results claims: no branded-drug trial outcomes presented as yours. Polsinelli reports NAD’s view that prescriber involvement alone doesn’t justify health claims.
4. Affiliate pages and advertorials: your claims, published by someone else. Send affiliates the phrase list in the table before their pages go live.
5. Sign-off: one named person approves new creative before it runs.

When GLP1.partners builds paid media for a GLP-1 telehealth brand, the ads and landing pages go through this list before launch.

FAQ

Is compounded semaglutide FDA approved?

No. FDA’s telehealth page states that “a compounded drug is not approved by FDA.”

What happens after an FDA warning letter?

The company has 15 business days from receipt to respond in writing to the address in the letter (the 2025 letters say “working days”). If it can’t fix everything in time, the letters ask for the reason for the delay and the time it will need.

Do Meta or Google have a compounded GLP-1 rule?

Not on their main drug policy pages, checked October 26, 2026.